Clinical Trials
28 trialsNCT02386800 2026-05-27
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
NCT05456191 2026-05-27
ASC4START
Novartis
Phase 3 Active not recruiting
NCT07354074 2026-05-26
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Phase 2 Recruiting
NCT04910685 2026-05-22
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
Blueprint Medicines Corporation
Phase 2/3 Recruiting
NCT05186753 2026-05-22
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT05362773 2026-05-22
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Phase 1 Recruiting
NCT07143669 2026-05-22
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Blueprint Medicines Corporation
Recruiting
NCT05534620 2026-05-20
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
medac GmbH
Phase 1 Completed
NCT07155226 2026-05-19
MOMENTUM
AstraZeneca
Phase 1/2 Recruiting
NCT02942290 2026-05-18
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)
AbbVie
Phase 1 Active not recruiting
NCT07454850 2026-05-18
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Novartis
Not yet recruiting
NCT07549516 2026-05-15
ASC2ADHERE
Novartis
Recruiting
NCT07469891 2026-05-14
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Phase 1 Recruiting
NCT02629692 2026-05-13
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Sun Pharma Advanced Research Company Limited
Phase 1/2 Terminated
NCT05320198 2026-05-13
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
Phase 1/2 Recruiting
NCT06499285 2026-05-13
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda
Phase 3 Recruiting
NCT07573111 2026-05-13
Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation
Laguna Biotherapeutics, Inc.
Phase 1 Not yet recruiting
NCT05583552 2026-05-12
IMpress
GCP-Service International West GmbH
Phase 2 Active not recruiting
NCT03975829 2026-05-11
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Recruiting
NCT04877522 2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT04817007 2026-05-08
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT06788509 2026-05-08
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT06915766 2026-05-08
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT07429266 2026-05-08
A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Ono Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05558696 2026-05-07
IMG-7289-CTP-203
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed
NCT04771572 2026-05-05
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
Phase 1 Recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT06313593 2026-05-04
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting